Clinical Trials Logo

Antiplatelet Drug clinical trials

View clinical trials related to Antiplatelet Drug.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06269432 Recruiting - Ischemic Stroke Clinical Trials

Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE(PATH-STROKE)

PATH-STROKE
Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

Objectives of Study:To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic cerebral infarction under the guidance of platelet aggregation function.

NCT ID: NCT06243133 Recruiting - Ischemic Stroke Clinical Trials

Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis

PATH-ICAS
Start date: January 25, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn about efficacy and safety of dual antiplatelet therapy in ischemic stroke with intracranial artery stenosis. The main question it aims to answer are: whether aspirin combined with clopidogrel for 3 month is better than 1 months for patients with non-cardiogenic cerebral infarction with intracranial artery stenosis. Participants will get dual antiplatelet therapy (aspirin plus clopidogrel) for 1 month or 3 months within 7 days of the first stroke. Researchers will compare experimental group (3 months dual antiplatelet therapy) with comparison group (1 month dual antiplatelet therapy), to see if experimental group would reduce stroke recurrence or mortality, and increase bleeding and other adverse prognosis.

NCT ID: NCT05852197 Recruiting - Clinical trials for Peripheral Arterial Disease

Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD

Start date: January 1, 2023
Phase:
Study type: Observational

Patients with PAD were grouped according to the combination of different anticoagulant and antiplate drugs. The type, dosage and duration of anticoagulant and antiplatelet drugs were recorded after operation. Major Adverse Cardiovascular Events and Major Adverse Limb Events were followed up at 1 month, 6 months and 12 months, respectively.